Current treatment strategy of diffuse large B-cell lymphomas.
Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting for approximately 25-30% of all new patients. Rituximab, a genetically engineered chimeric monoclonal antibody that specifically binds to CD20, is the first monoclonal antibody approved for the treatment of B-cell lymphoma. Rituximab significantly improves treatment outcome in DLBCL. A large-phase III study demonstrated improved overall survival (OS) in patients with DLBCL treated with R-CHOP therapy. The Groupe d'Etude des Lymphomes de l'Adulte (GELA), Eastern Cooperative Oncology Group (ECOG) and German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) studies designed for patients older than 60 years have clearly shown prolonged event-free survival (EFS) and OS among patients who received rituximab and chemotherapy. For patients under 60 years, the MabThera International Trial Group (MInT) study demonstrated improved EFS and OS after the addition of rituximab to CHOP therapy. However, the R-CHOP therapy does not provide a satisfactory treatment outcome in the high-risk group according to the international prognostic index. Therefore, R-CHOP therapy is the new standard therapy in elderly and young, low-risk DLBCL patients. For young, high-risk DLBCL patients, treatment that incorporates rituximab and hematopoietic stem cell transplantation has been administered in clinical studies.
Niitsu
Nozomi
N
Department of Hematology, Saitama Medical University, Hidaka, Saitama, Japan. nniitsu@saitama-med.ac.jp
D000367:Age Factors; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy / Q000628:therapy*
Cancer Treat Rev. 2007 Jun;33(4):338-46
17400393
Blood. 2004 Aug 1;104(3):626-33
14982884
Ann Intern Med. 1985 May;102(5):596-602
2580468
J Clin Oncol. 2007 Mar 1;25(7):787-92
17228021
Blood. 2002 Feb 1;99(3):754-8
11806974
J Clin Oncol. 2005 Jun 20;23(18):4117-26
15867204
N Engl J Med. 2002 Jan 24;346(4):235-42
11807147
Lancet Oncol. 2006 May;7(5):379-91
16648042
N Engl J Med. 1993 Apr 8;328(14):1002-6
7680764
Lancet Oncol. 2008 Feb;9(2):105-16
18226581
J Clin Oncol. 2004 Aug 1;22(15):3032-8
15210738
N Engl J Med. 1993 Sep 30;329(14):987-94
8141877
Blood. 2003 Dec 15;102(13):4284-9
12920037
N Engl J Med. 1998 Jul 2;339(1):21-6
9647875
Cancer. 1978 Oct;42(4):1705-10
361209
Haematologica. 2006 Jan;91(1):96-103
16434377
J Clin Oncol. 2006 Jul 1;24(19):3121-7
16754935
Blood. 1994 Jan 15;83(2):435-45
7506951
J Clin Oncol. 2008 May 10;26(14):2258-63
18413640
Hematol Oncol. 2010 Jun;28(2):68-74
20235332
Leukemia. 2009 Apr;23(4):777-83
19151788
N Engl J Med. 2005 Mar 24;352(12):1197-205
15788496
J Clin Oncol. 1991 Jan;9(1):25-38
1702144